---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-26-053902"
form_type: "8-K"
ticker: "DCTH"
cik: "0000872912"
company_name: "DELCATH SYSTEMS, INC."
filed_at: "2026-08-06T12:10:00+00:00"
generated_at: "2026-08-06T12:15:32.734662+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Delcath Q2 revenue $29.1M, up 20% YoY; raises FY 2026 revenue guidance to $104-108M

## Summary
- Total revenue $29.1M (Q2 2026) vs $24.2M (Q2 2025); HEPZATO KIT $27.1M, CHEMOSAT $2.0M.
- Net income $2.7M (flat YoY); non-GAAP adjusted EBITDA $7.6M vs $9.8M prior year.
- Cash and investments $95.9M, no debt as of June 30, 2026.
- FY 2026 revenue guidance raised to $104-108M (≥28% HEPZATO volume growth); gross margins 86-89%.
- 31 active treatment centers; HEPZATO volume grew ~30% YoY in Q2.

## SEC filing metadata
- accession: 0001628280-26-053902
- form_type: 8-K
- ticker: DCTH
- cik: 0000872912
- company_name: DELCATH SYSTEMS, INC.
- filed_at: 2026-08-06T12:10:00+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/872912/000162828026053902/0001628280-26-053902-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/872912/000162828026053902/dcth-20260806.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-26-053902
- JSON: https://secwatch.observer/filing/0001628280-26-053902.json
- Plain text: https://secwatch.observer/filing/0001628280-26-053902.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.